FDA rolls back COVID-19 vaccine policy to take new ‘evidence-based approach’

Healthcare cure concept with a hand in blue medical gloves holding Coronavirus, Covid 19 virus, vaccine vial

Photo: Adobe Stock

The Food and Drug Administration (FDA) published new Evidence-Based guidelines for COVID-19 vaccination recommendations in the New England Journal of Medicine on Tuesday. 

These guidelines are focused on reducing the massive marketing campaign to promote Covid-19 vaccine boosters for children and healthy adults, noting that the benefits of continued vaccinations for healthy adults remain “uncertain.”

The paper indicates that “public trust in vaccination in general has declined.” 

This has resulted in dwindling support numbers. “Less than 25% of Americans received boosters each year, ranging from less than 10% of children younger than 12 years of age in the 2024–2025 season to 50% of adults over 75 years old.”

“Even health care workers remain hesitant, with less than one third participating in the 2023–2024 fall booster program,” the authors added. 

The FDA then revealed that it will adopt new guidelines that must deliver “proof that a vaccine can generate antibody titers in people,” and approach COVID-19 vaccine recommendations for healthy individuals (ages 6 months through 64 years old) with “randomized, controlled trial data evaluating clinical outcomes before Biologics License Applications can be granted.”

“These clinical trials will inform future directions for the FDA, but more important, they will provide information that is desperately craved by health care providers and the American people.”

The new policy also prioritizes giving COVID-19 vaccine access to individuals with underlying medical conditions instead of offering every American a “one-size-fits-all” approach.

Health Secretary Robert F. Kennedy Jr. also addressed the U.S. Senate Committee during Tuesday’s 2026 Health and Human Services budget hearing, emphasizing the need for changes in U.S. vaccine approaches.  

He reminded lawmakers of the importance of properly conducted clinical trials, stating, “Placebo-controlled trials are gold-standard science. We can conduct vaccine studies without subjecting people to unethical experiments.”

Kennedy has strongly advocated for increased vaccine testing to ensure maximum benefits and properly evaluate potential side effects. This would allow Americans to make informed health decisions based on tangible medical evidence. 

This new approach aims to restore trust in the government’s health department by making it more reliable. It is driven by Kennedy’s mission to Make America Healthy Again. 

Related posts

Sen. Blackburn reintroduces bill targeting birth tourism

White House says 2031 U.S. Women’s World Cup must prohibit males from competition

President Trump weighs expanding Canada tariffs over wildfire smoke